• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Cohance Lifesciences Limited — Board Meeting, 12-02-2026: Outcome of Board Meeting

    12-02-2026 | 05:07 pm

    Cohance Lifesciences' board approved Q3 & 9M FY26 consolidated results. Q3 revenue was ₹544.6 Cr (down 19.5%) and 9M revenue ₹1,649.4 Cr (down 6.7%). Adjusted EBITDA also saw declines. FY26 is a transition year, with the company focusing on execution and expecting a return to revenue growth in FY27.

    No comments yet. Be the first to comment!

    All announcements from Cohance Lifesciences Limited